ArticleSkeletal radiology2026
Rheumatoid arthritis: transarterial microembolization for refractory localized joint inflammation.
Article in Skeletal radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Transarterial microembolization targets periarticular neovascularization in localized joint pain that persists despite systemic therapy. We report a 31-year-old woman with rheumatoid arthritis involving the elbow, knee, and ankle. The patient underwent selective transarterial microembolization, with intra-arterial imipenem/cilastatin delivered to angiographically identified neovessels. Post-embolization angiography demonstrated decreased hypervascularity. Over 12 months, pain and function improved, and magnetic resonance imaging showed reduced synovial proliferation, periarticular edema, and bone marrow edema. The systemic therapy regimen was maintained unchanged during follow-up. Adverse events were transient and limited to brief procedure-related pain and localized skin discoloration. These observations are hypothesis-generating and support prospective evaluation of TAME as a localized adjunct to systemic immunomodulation.
Indexed as
Identifiers
42149217What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.